Global neuromodulation in epilepsy market was valued at US$ 1365.89 million in 2020 and is expected to reach US$ 3410.12 million by 2029, growing at an estimated CAGR of 10.71% over the forecast period. Neuromodulation for epilepsy is considered to be an alternative to traditional epilepsy surgical approaches. The same can be bifurcated into two types which is invasive and non-invasive. The U.S. Food and Drug Administration (FDA) granted approval for the use of Deep Brain Stimulation (DBS) therapy by Medtronic as a treatment option for focal epilepsy. Approximately one million people in the United States suffer from uncontrolled epilepsy. It has been duly reported that the total number of seizures decreased by 40% in people who received DBS treatment compared to 15% for those who did not receive DBS treatment. Research and development activities are being undertaken to incorporate seizure forecasting and responsive stimulation into DBS for epilepsy. A project assisted through the NIH BRAIN Initiative Public-Private Partnership Program is expected to conduct clinical research using industry-supplied cutting-edge devices.
Access the Full Report @ https://www.absolutemarketsinsights.com/reports/Neuromodulation-in-Epilepsy-Market-2019-2027-276
Rising demand for minimally invasive procedures is expected to aid the overall neuromodulation in epilepsy market. Non-invasive vagus nerve stimulation devices which do not require surgical implantation have been approved in the European Union to treat epilepsy. A company named LivaNova, a London-based medical medical device manufacturer received an approval for its responsive epilepsy treatment system. Single-pulse and paired-pulse TMS techniques are commonly used to quantify levels of inhibition and cortical excitability. However, their interside and longitudinal intraindividual variability is lower. The recent technological and methodological advances particularly in this field has aided the patients suffering from epilepsy disorders in the recent past and is expected to continue the same trend over the forecast period. The treatment is primarily offered to people who have not responded properly to drug treatment, thus, improving and restoring their overall quality of life.
The report provides both, qualitative and quantitative research of neuromodulation in epilepsy market, as well as provides comprehensive insights and favored development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contracts adopted by these major market participants are also recognized and analyzed in the report. For each company, the report studies their global presence, competitors, service offerings, specification, pricing, and gross margin.
Some of the players operating in the neuromodulation in epilepsy market are Abbott Laboratories, Boston Scientific Corporation, LivaNova PLC, Medtronic, NeuroPace, Inc. amongst others.
Purchase the latest in-depth report @ https://www.absolutemarketsinsights.com/checkout?id=276
Neuromodulation in Epilepsy Market:
By Therapy Type
- Vagus Nerve Stimulation (VNS)
- Deep Brain Stimulation (DBS)
By Magnetic Stimulation Technique
- Single pulse
- Repeated pulse
By Region
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Contact Us:
Company: Absolute Markets Insights
Email Id: sales@absolutemarketsinsights.com
Phone: IN +91-740-024-2424, US +1-510-420-1213
Contact Name: Shreyas Tanna
Website: www.absolutemarketsinsights.com
